Applied Spine Technologies reports Stabilimax NZ® clinical trial milestone: enrollment surpasses 100 patients; 5 new sites added, boosting total to 21 -- Company's "motion preserving" Stabilimax NZ® device is designed to treat one of the most common indications for spinal surgery: Lumbar Spinal Stenosis (LSS)

Share Article

Applied Spine Technologies (“AST”) reported today that it has reached a clinical trial milestone related to its “motion preserving” Stabilimax NZ® Dynamic Spine Stabilization System: the randomized, controlled study recently enrolled its 100th patient. The study is comparing posterior dynamic stabilization in patients using the Stabilimax NZ device to patients receiving traditional fusion surgery to treat their Lumbar Spinal Stenosis, a common lower-back disorder where deterioration of the joints and discs leads to increased pressure on the spinal nerves.

News Image
Our Stabilimax NZ clinical trial has gained significant traction in the past few months

AST also announced that it has added five new clinical sites to its study, bringing the total number of investigative sites to 21. The new sites are: Lehigh Valley Hospital (Allentown, Pa.), Littleton Adventist Hospital (Littleton, Colo.), Morton Plant Hospital (Clearwater, Fla.), Sacred Heart Hospital (Eugene, Ore.), and The Hospital of Central Connecticut (New Britain, Conn.).

"Our Stabilimax NZ clinical trial has gained significant traction in the past few months," said Thomas E. Wood, President and CEO of Applied Spine Technologies. "This momentum is the combination of selecting great community hospitals with enthusiastic private practice groups. In fact, we expect to add another five to seven sites soon. Spine fusion used to be the only option for patients suffering from chronic back pain. Our clinical investigators understand that Stabilimax NZ is designed to be a dramatic advance in back pain treatment by stabilizing the spine without eliminating motion."

Lumbar Spinal Stenosis is one of the most common indications for spinal surgery in the United States. It is estimated that as many as 400,000 Americans may be suffering from the symptoms of LSS [source: American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS)], and this number is expected to grow over the next decade.

About Applied Spine Technologies

Applied Spine Technologies is a medical device company focused on thought leadership in motion preservation of the lumbar spine. The company maintains a deep understanding of the unmet clinical and biomechanical needs in spine surgery and has developed Stabilmax NZ® in an attempt to address these needs. The Stabilimax NZ® is a dynamic stabilization system aimed to improve the long-term surgical outcomes of low back surgery without the need for fusion. The Stabilmax NZ® is available for investigational use only and is currently being evaluated in a multi-center clinical trial. For more information, visit the company website at http://www.appliedspine.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ronald C. Trahan
Ronald Trahan Associates, Inc.
508-359-4005, x108
Email >